Press-release for stocks related to approval for abbv

RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval
Published: 2022-10-21 (Crawled : 21:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| Email alert Add to watchlist
rinvoq fda approval

Neurologic Disorders Therapeutics Market Size to Grow by USD 33.46 billion, Approval Of Novel Drugs to Boost Market Growth - Technavio
Published: 2022-08-03 (Crawled : 04:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510

Health Technology

| -3.23% | O: -1.8% H: 0.2% C: 0.0%
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -8.03% | O: -2.6% H: 0.0% C: -0.76%
NPCE S | $14.07 2.33% 2.27% 65K

Manufacturing

| 138.3% | O: 0.52% H: 3.71% C: -2.93%
NVS | $92.57 -0.55% 0.0% 910K

Health Technology

| 9.43% | O: 0.11% H: 0.31% C: -0.34%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| -3.84% | O: -0.29% H: 0.24% C: -0.58%
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 16.94% | O: 0.32% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -8.18% | O: -0.17% H: 0.12% C: -1.29%
BIIB | $190.55 -0.84% -0.84% 1.5M

Health Technology

| -6.69% | O: 0.41% H: 3.35% C: 1.71%
ACAD | $17.08 -0.64% -0.64% 990K

Health Technology

| 14.66% | O: 2.47% H: 2.8% C: -2.67%
approval therapeutics growth market

CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis
Published: 2022-06-27 (Crawled : 07:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 9.57% | O: 1.55% H: 0.0% C: 0.0%
rinvoq treatment active chmp approval

SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Published: 2022-06-17 (Crawled : 12:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 21.05% | O: 1.05% H: 0.0% C: 0.0%
il-23 skyrizi fda disease active approval

CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis
Published: 2022-05-23 (Crawled : 07:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 8.34% | O: -0.51% H: 0.0% C: 0.0%
rinvoq treatment chmp approval ulcerative colitis

BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval
Published: 2022-04-13 (Crawled : 16:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| -1.29% | O: -1.38% H: 0.0% C: -3.67%
botox fda approval

Global Pharmaceutical API Manufacturing Market Report 2022-2030: Stringent Regulations for Approval of Pharmaceutical Drugs Restraining Growth
Published: 2022-04-12 (Crawled : 17:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560

Health Technology

| -1.92% | O: -0.86% H: 1.21% C: 1.21%
NVSEF | $93.6375 6.88% 82K

Health Technology

| 23.0% | O: 0.16% H: 0.22% C: 0.22%
NVS | $92.57 -0.55% 0.0% 910K

Health Technology

| -0.71% | O: -0.48% H: 0.09% C: -0.68%
GSK | $39.27 -0.83% 0.01% 2.2M

Health Technology

| -15.65% | O: -0.36% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 143.0% | O: -0.77% H: 0.99% C: 0.49%
ALB | News | $111.8 -2.26% 0.63% 2.2M

Process Industries

| -44.42% | O: 1.31% H: 2.06% C: -1.76%
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| -2.75% | O: -0.31% H: 0.74% C: -1.18%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -21.37% | O: -3.25% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M

Health Technology

| -3.35% | O: -2.32% H: 0.43% C: -0.55%
report approval growth market drug

AbbVie's Rinvoq Breaks into Gastroenterology Space with UC Approval
Published: 2022-03-17 (Crawled : 15:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 5.84% | O: 0.72% H: 0.92% C: 0.9%
space approval rinvoq spac

RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2022-03-16 (Crawled : 22:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 5.84% | O: 0.72% H: 0.92% C: 0.9%
rinvoq treatment fda fda approval approval active ulcerative colitis

AbbVie Prepares to Seek Supplemental Approval for Migraine Treatment
Published: 2022-03-10 (Crawled : 19:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 11.51% | O: -0.11% H: 0.0% C: 0.0%
treatment approval migraine

Cervical Dystonia Therapeutics Market Size to Grow by USD 154.77 Million | Market Research Insights Highlight expected Approval of Late-stage Pipeline Molecules as Key Driver | Technavio
Published: 2022-02-07 (Crawled : 07:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 18.07% | O: 0.8% H: 0.0% C: 0.0%
research approval therapeutics

Celltrion Healthcare announces Canadian approval of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 19.75% | O: -0.67% H: 0.0% C: 0.0%
health thc approval cel humira biosimilar

RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
Published: 2021-12-14 (Crawled : 01:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 31.28% | O: 1.81% H: 0.0% C: 0.0%
rinvoq fda fda approval approval

AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis
Published: 2021-11-17 (Crawled : 09:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology

| 41.53% | O: -0.09% H: 0.87% C: 0.64%
treatment europe immunology risankizumab approval

New Relief for Migraine Sufferers as FDA Approves AbbVie's Atogepant
Published: 2021-09-29 (Crawled : 16:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M

Health Technology